RecruitingNCT06489769

Opioid Misuse in Patients with Cancer

Prevalence of Opioid Misuse in Patients with Cancer


Sponsor

Rigshospitalet, Denmark

Enrollment

200 participants

Start Date

Jan 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The success of opioid treatment in terminally ill cancer patients set the stage for extending the same treatment principles to the treatment of all chronic pain conditions including chronic non-cancer pain and chronic pain in cancer, where survival and long-standing chronic disease trajectories are getting more prevalent due to increasing survival rates. In this context, opioid misuse as such has been highly neglected - especially in palliative care, but also in cancer pain management in general. Previous studies have explored the literature on opioid misuse among adult cancer patients, noting that the available evidence is still in its early stages. Limited prospective studies with a wide range of definitions and methodologies for assessing misuse exist. Therefore, it seems highly relevant and justified to study the prevalence of opioid misuse risk in patients with cancer. The hypothesis of this study is that opioid misuse is not uncommon in Danish patients in treatment with opioids for cancer-related pain. Thus, the prevalence of opioid misuse risk among patients with cancer in Danish palliative care units will be investigate.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Outpatients ≥ 18 years,
  • patients who are treated with opioids due to cancer-related pain.

Exclusion Criteria4

  • Patients who do not master the Danish language in speech and writing,
  • Patients who have severe cognitive dysfunction,
  • Patients who are not treated with opioids,
  • Patients who refused to participate in the study.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Rigshospitalet

Copenhagen, København Ø., Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06489769


Related Trials